News blog

FDA approves antisense cholesterol drug

The US Food and Drug Administration announced yesterday that it has approved Kynamro (mipomersen), an “antisense” drug designed to treat a rare condition that causes the accumulation of extremely high levels of “bad” LDL cholesterol. Antisense drugs are strands of nucleic acid, such as DNA, designed to bind to and inactivate the RNA produced by a given gene. 

BACK TO ARTICLE

Your details are incomplete or incorrect, please amend the following information

%s

Tell a Friend

Your friend's email address (Required)

Your email (Required)

Message subject (Required)

Message

Verify (Required)

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE